Carfilzomib plus melphalanprednisone in elderly patients with newly diagnosed multiple myeloma

Age and ageing in blood disorders

Rituximab for b-cell lymphoma and EHA overview

Highlights from EHA 2013

Patient advocacy track 'personalised medicine'

Second line treatment of multiple myeloma with melphalan prednisone and lenalidomide

Challenges facing haematologists treating acute myeloid leukaemia

JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms

Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma

Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia

Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelofibrosis

Strategies to maintain remission in high risk CD19 lymphoid malignancies